NASDAQ:CGEN

Compugen - CGEN News Today

$0.87

0.00 (0.00%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.85
▼
$0.89
50-Day Range: $0.65
▼
$1.20
52-Week Range: $0.51
▼
$3.68

Volume: 439,341 shs
Average Volume: 603,001 shs
Market Capitalization: $75.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.40

Institutional Ownership

Get Compugen News Delivered to You Automatically

CGEN Media Mentions By Week

CGEN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CGEN
News Sentiment
▼
0.36

0.70
▲
Average
Medical
News Sentiment

CGEN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CGEN Articles
This Week
▼
4

2
▲
CGEN Articles
Average Week

Source

Source	Headline
	Compugen Ltd. (NASDAQ:CGEN) Receives $6.67 Average Price Target from Analysts americanbankingnews.com - January 25 at 3:48 AM
	Brokerages Set Compugen Ltd. (NASDAQ:CGEN) Target Price at $6.67 americanbankingnews.com - January 25 at 3:48 AM
	Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview finance.yahoo.com - January 23 at 7:27 AM
	Why Shares of Compugen Rose on Thursday finance.yahoo.com - January 6 at 8:05 AM
	Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer finance.yahoo.com - December 14 at 2:09 AM
	Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients finance.yahoo.com - December 1 at 7:49 PM
	Why Shares of Compugen Rose 16.5% on Wednesday finance.yahoo.com - November 30 at 5:32 PM
	Why Shares of Compugen Jumped 17.86% on Thursday msn.com - November 19 at 6:24 PM
	Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT Bispecific finance.yahoo.com - November 16 at 4:07 PM
	Why Compugen Stock Crumbled Today finance.yahoo.com - November 15 at 5:51 AM
	Compugen Reports Third Quarter 2022 Results finance.yahoo.com - November 14 at 12:04 PM
	SVB Securities Sticks to Its Buy Rating for Compugen (CGEN) markets.businessinsider.com - November 11 at 5:41 AM
	Compugen to Participate in the Stifel Healthcare Conference finance.yahoo.com - November 8 at 11:17 AM
	Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients finance.yahoo.com - November 7 at 11:45 AM
	Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients finance.yahoo.com - November 7 at 11:45 AM
	Compugen Announces Receipt of Nasdaq Delisting Notice finance.yahoo.com - November 2 at 7:34 PM
	Compugen to Present New Clinical Data at ESMO-IO finance.yahoo.com - October 26 at 8:38 AM
	CGEN.TA - Compugen Ltd. \| Stock Price & Latest News \| Reuters reuters.com - October 22 at 10:44 PM
	Computational Biology Global Market Report 2022: Featuring Accelrys, Certara, Chemical Computing Group, Compugen & Entelos - ResearchAndMarkets.com - Business Wire businesswire.com - October 18 at 11:46 PM
	CGEN.A - Compugen Ltd. (USA) \| Stock Price & Latest News \| Reuters reuters.com - October 15 at 2:07 PM
	Head and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain \| DelveInsight - GlobeNewswire globenewswire.com - October 10 at 1:31 PM
	Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022 finance.yahoo.com - October 6 at 7:51 AM
	Computational Biology Global Market Report 2022 - Yahoo Finance UK uk.finance.yahoo.com - September 30 at 3:13 PM
	Compugen Letter to Shareholders - Yahoo Finance finance.yahoo.com - September 23 at 10:36 AM
	Compugen Letter to Shareholders finance.yahoo.com - September 22 at 9:38 AM
	Compugen Ltd CGEN Stock Quote morningstar.com - September 15 at 8:34 PM
	Compugen Names Alberto Sessa CFO, Effective Nov. 1 nasdaq.com - September 12 at 11:59 AM
	Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer finance.yahoo.com - September 12 at 11:59 AM
	Shareholders in Compugen (NASDAQ:CGEN) are in the red if they invested a year ago finance.yahoo.com - September 1 at 5:22 PM
	These 2 'Perfect' Indicators Say the Bear Market Is Over - InvestorPlace investorplace.com - August 26 at 1:22 AM
	FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL - Yahoo Canada Finance ca.finance.yahoo.com - August 25 at 12:19 AM
	Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan finance.yahoo.com - August 24 at 9:38 AM
	Analyst Ratings for Compugen - Benzinga benzinga.com - August 23 at 11:37 PM
	Truist Securities Maintains Buy Rating for Compugen: Here's What You Need To Know markets.businessinsider.com - August 23 at 6:37 PM
	Analyst Ratings for Compugen markets.businessinsider.com - August 23 at 6:37 PM
	CGEN.OQ - Compugen Ltd. (USA) \| Stock Price & Latest News \| Reuters reuters.com - August 22 at 6:19 PM
	Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities - Yahoo Finance finance.yahoo.com - August 12 at 10:49 AM
	JMP Securities Maintains Market Outperform Rating for Compugen: Here's What You Need To Know msn.com - August 8 at 11:07 PM
	This Analyst Lowers Price Target On Lyft; Also Check Out Some Other Major PT Changes - Benzinga benzinga.com - August 8 at 5:45 PM
	Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio finance.yahoo.com - August 8 at 5:44 PM
	Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2022 Results - Earnings Call Transcript seekingalpha.com - August 5 at 10:21 AM
	Compugen GAAP EPS of -$0.11 beats by $0.01 (NASDAQ:CGEN) - Seeking Alpha seekingalpha.com - August 5 at 5:21 AM
	Compugen Tops Q2 EPS by 1c By Investing.com - Investing.com investing.com - August 4 at 2:20 PM
	Compugen Tops Q2 EPS by 1c By Investing.com - Investing.com India in.investing.com - August 4 at 9:19 AM
	Compugen Reports Second Quarter 2022 Results finance.yahoo.com - August 4 at 9:19 AM
	Earnings Preview For Compugen - Benzinga benzinga.com - August 3 at 6:18 PM
	Compugen Q2 2022 Earnings Preview (NASDAQ:CGEN) - Seeking Alpha seekingalpha.com - August 3 at 1:17 PM
	Compugen to Release Second Quarter Results on Thursday, August 4, 2022 finance.yahoo.com - July 29 at 1:15 AM
	One Chart Proves That Tech Stocks Are Due for a Huge Breakout! - Nasdaq nasdaq.com - July 28 at 8:49 AM
	vTv Therapeutics (VTVT) Appoints Paul Sekhri as President and CEO - StreetInsider.com streetinsider.com - July 27 at 12:47 PM

Get Compugen News Delivered to You Automatically

This page (NASDAQ:CGEN) was last updated on 1/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Compugen - CGEN News Today

CGEN Media Mentions By Week

CGEN Media Sentiment

CGEN News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info